Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535744 | 0.80 | RHEB (0.55) | RHEB | |
| SCHEMBL23706115 | 0.73 | RHEB (0.55) | RHEB | |
| SCHEMBL30096998 | 0.73 | RHEB (0.55) | RHEB | |
| SCHEMBL27778367 | 0.72 | RHEB (0.36) | RHEBGPR17 | |
| SCHEMBL19252211 | 0.72 | GPR17 (0.32) | GPR17 | |
| SCHEMBL21624065 | 0.72 | KEAP1 (0.41) | GPR17 | |
| SCHEMBL23452293 | 0.71 | RHEB (0.47) | RHEB | |
| SCHEMBL20535442 | 0.70 | RHEB (1.00) | RHEBGPR17 | |
| SCHEMBL20535356 | 0.70 | RHEB (1.00) | RHEB | |
| SCHEMBL21624049 | 0.70 | KDM4E (0.51) | RHEBGPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
| EP-1395590-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-A]INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094830-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | RHEB 4490/4885GPR17 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.